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Objective: To compare the efficacy of ciclesonide (80 mg/day) with fluticasone propionate
(200 mg/day) in mild to moderate persistent asthma.
Methods: Patients aged 12e75 years and previously treated with low doses of inhaled cortico-
steroid (fluticasone propionate 250 mg/day or equivalent) entered a 2e4 week run-in period
during which only rescue medication was permitted. For inclusion into the double-blind,
24-week treatment period, patients had to show a forced expiratory volume in 1s (FEV1) of
61e90% predicted and a decrease in FEV1 during run-in of 10%. Patients (n Z 480) were
randomized to ciclesonide 80 mg (ex-actuator) once daily in the evening or fluticasone propi-
onate 100 mg (ex-valve) twice daily. The primary efficacy variable was the change from base-
line in FEV1. Secondary efficacy variables included asthma control and asthma-specific quality
of life.
Results: Both treatments significantly increased FEV1 and other lung function variables
from baseline (p < 0.0001, both groups, all variables). The least squares mean increases
in FEV1 were 0.46L (ciclesonide) and 0.52L (fluticasone propionate); non-inferiority of
ciclesonide to fluticasone propionate was demonstrated (p Z 0.0002, per-protocol anal-
ysis). Five patients in each group experienced asthma exacerbations. Improvements in
the percent of days with asthma control (days with no asthma symptoms and no use
of rescue medication) and asthma-specific quality of life were comparable between
treatments.49 2085; fax: þ45 8949 2110.
. Dahl).
0 Published by Elsevier Ltd.
1122 R. Dahl et al.Conclusions: The study confirmed similar efficacy of ciclesonide 80 mg once daily and fluti-
casone propionate 100 mg twice daily in mild to moderate persistent asthma. The low dose
of ciclesonide was efficacious during long-term treatment.
EudraCT number: 2004-001072-39.
ª 2010 Published by Elsevier Ltd.Introduction
Bronchial asthma is one of the most common chronic
diseases worldwide and accounts for 1% of the total annual
global burden of disease.1 There is still no cure for asthma,
but pharmacological therapy can either provide acute
symptom relief or tackle the underlying inflammatory
processes to achieve clinical control of asthma on a long-
term basis. Inhaled corticosteroids are currently the most
effective anti-inflammatory agents in asthma therapy and
are recommended by national and international guidelines
as first-line treatment for persistent asthma, either alone or
in combination with long-acting beta-agonists.2,3
Ciclesonide is a glucocorticosteroid-ester prodrug,
currently approved for the treatment of persistent asthma in
more than 50 countries. It is formulated as a solution for
inhalation by means of a pressurized metered-dose inhaler
(MDI) with hydrofluoroalkane (HFA) 134a as a propellant.
Efficacy of ciclesonide has been demonstrated in numerous
placebo-controlled and comparative studies in adults and
children with asthma of all severities.4,5 In Europe, the rec-
ommended starting dose of ciclesonide in adolescents and
adults is 160 mg once daily. A lower dose of ciclesonide, 80 mg
once daily, significantly improved lung function variables
compared with placebo in patients with mild to moderate
persistent asthma in two 12-week studies.6,7 In addition,
ciclesonide 80 mg once daily attenuated the early and late
asthmatic responses after allergen challenge and significantly
improved exercise-induced bronchoconstriction after one
week of treatment.8,9 A comparative 12-week study in
patients with persistent asthma (12 years) showed similar
asthma control of two doses of ciclesonide, 80 mg and 160 mg
(ex-actuator) once daily, and fluticasone propionate 100 mg
(ex-valve) twice daily.10
Many patients with persistent asthma require long-term
anti-inflammatory treatment for the prevention of asthma
symptoms. To minimize the risk of side effects, the lowest
effective dose of an inhaled corticosteroid should be used
for maintenance treatment. The main objective of the
present study was to confirm the long-term efficacy of
ciclesonide 80 mg (ex-actuator) once daily over 24 weeks in
patients with mild to moderate asthma. For this purpose,
ciclesonide was compared with fluticasone propionate
100 mg (ex-valve) twice daily.
Methods
Patients
Female and male patients aged 12e75 years with a history of
persistent bronchial asthma11 for at least 6 months, but
otherwise in goodhealthwereenrolled. Patientswereeligible
to enter a 2e4 week run-in period prior to randomization(baseline) if they had received inhaled corticosteroids (fluti-
casone propionate 250 mg/day or equivalent) at a constant
dose during the last 4 weeks prior to the run-in period and if
they exhibited a forced expiratory volume in 1s (FEV1)
between 80% and 105% predicted. Patients were excluded
from the study if they had: other relevant lung diseases, e.g.,
chronic obstructive pulmonary disease, a severe concomitant
disease, a condition that precluded the use of inhaled corti-
costeroids, or clinically relevant abnormal laboratory values.
Female patients were excluded if they were pregnant,
breastfeeding, or were not using reliable contraceptive
methods. Current smokers and ex-smokers with 10 pack-
years, patients starting immunotherapy, and patients with
known or suspected hypersensitivity to inhaled corticoste-
roids or excipients of the metered-dose inhaler were also
excluded. Systemic glucocorticosteroids were not to be used
during the last 4 weeks or more than twice during the last 6
months prior to the run-in period.
For inclusion into the treatment period at baseline,
patients had to have a FEV1 between 61% and 90% pre-
dicted, a decrease in FEV1 of 10% compared to the start of
the run-in period, and reversible bronchial obstruction
(DFEV1  12% predicted or 0.20L) after inhalation of
200e400 mg salbutamol. Patients were not to be random-
ized to treatment if they had a daytime asthma symptom
score of 3 (5-point scale: 0e4) on more than 3 days or
nighttime asthma symptoms on more than 2 nights during
the last 7 days prior to randomization.
Study design
This was an international, multicentre, randomized, double-
blind, double-dummy, 2-arm, parallel-group study with
a 2e4 week run-in period (up to 4 visits) and a 24-week
double-blind treatment period (6 visits). During the run-in
period, patients received only rescue medication (inhaled
salbutamol, 100 mg/puff) according to need. Patients who
met the criteria for entering the treatment period were
randomly assigned in a 1:1 ratio to receive ciclesonide 80 mg
(ex-actuator) once daily in the evening or fluticasone
propionate 100 mg (ex-valve) twice daily in the morning and
evening (200 mg/day, equivalent to an ex-actuator dose of
176 mg/day). Study medications were administered via HFA-
MDI. No spacer was used, but inhalation technique was
reviewed at each visit during the treatment period. No other
anti-asthma drugs, with the exception of rescuemedication,
were permitted during the treatment period.
Randomization was based on a computer-generated list
(Program RANDOM).12 The study was conducted at 48 centres
in Austria, Canada, Germany, Poland, and South Africa in
accordance with the principles of the revised Declaration of
Helsinki (Somerset West, 1996) and the International
Conference on Harmonization Topic E6: Guideline for Good
24-week efficacy of low-dose ciclesonide and fluticasone 1123Clinical Practice (CPMP 135/95). The study protocol, patient
information and consent form were approved by the relevant
Independent Ethics Committees or Institutional Review
Boards. All adult patients and parents or legal guardians of
adolescents gave written informed consent before
enrolment.
Efficacy assessments
FEV1 and forced vital capacity (FVC) were recorded at the
time of randomization (baseline) and after 2, 4, 8, 16, and
24 weeks of treatment. Spirometry was performed
according to the standards set by the American Thoracic
Society.13 At each centre, the same spirometry equipment
was used during the entire study period and the same
person performed the measurements, if possible. Lung
function was measured after a 15e30 min rest between 6
and 10 a.m., approximately 12 h after the last use of study
medication and at least 4 h after the last use of rescue
medication. The highest of three technically acceptable
readings was recorded in the patient’s case report form.
Peak expiratory flow (PEF) was recorded daily by the
patients using the Mini-Wright peak flow meter (Clement
Clarke International Limited, Essex, UK) immediately after
rising from bed in the morning and before inhaling the study
medication. The highest of three recorded values was used
for further evaluation.
For daily evaluation of asthma control, patients recor-
ded their asthma symptoms (daytime and nighttime) and
the use of rescue medication (salbutamol) in their diary. A
day with asthma control was defined as a day with no
asthma symptoms and with no use of rescue medication.
Asthma symptoms were rated on a 5-point scale, where
0 represented no asthma-related symptoms and 4 the
highest discomfort due to asthma-related symptoms.
Patients who experienced an asthma exacerbation, defined
as a deterioration of asthma that required treatment with
oral corticosteroids, were withdrawn from the study.
Asthma-specific quality of life was assessed using the self-
administered, standardized version of the Asthma Quality of
Life Questionnaire (AQLQ[S]),14,15 which consists of 32
questions in 4 domains: activity limitations, symptoms,
emotional function, and exposure to environmental stimuli.
Patients completed the questionnaire at baseline and at
week 8, 16, and 24 (or study end) and responded to each
question on a 7-point scale from 1 (maximal impairment) to 7
(no impairment). The net benefit in quality of life was
calculated as the proportion of patients with an increase of
at least 0.5 in the overall AQLQ(S) score (improvement)
minus the proportion of patients with a decrease of at least
0.5 in the overall AQLQ(S) score (deterioration).Tolerability and safety assessments
Adverse events (AEs) were recorded at each study visit. The
investigator classified the intensity of an AE as mild,
moderate, or severe and assessed the causal relationship
between the AE and the administration of study medica-
tion. The patient’s oropharynx was inspected at each visit
and a swab test was performed if oral candidiasis was sus-
pected. Vital sign measurements (blood pressure, heartrate), physical examinations, and clinical laboratory tests
were performed at the beginning of the run-in period and
after 24 weeks of treatment (or at the time of premature
discontinuation).
Statistical analysis
Efficacy variables were analyzed on both an intention-to-
treat (ITT) and a per-protocol (PP) basis. Patients who had
a baseline value of efficacy and who had received at least
one dose of ciclesonide or fluticasone propionate were
included in the ITT analysis. The PP analysis was based on
patients of the ITT population without major protocol
violations. The safety analysis included all randomized
patients who had received at least one dose of study medi-
cation (ITT population).
The primary efficacy variable was the change in FEV1 [L]
from baseline to the end of the treatment period (week 24 or
last [valid] recorded measurement). Secondary efficacy
variables included changes in FVC from baseline to all
scheduled visits, the difference in the average of morning
PEF of the week before baseline and the last week of
treatment, the proportion of patients with asthma exacer-
bations, the difference in the average percentage of days
with asthma control of the last 14 days before baseline and
the last 28 days of treatment, and the change from baseline
to the end of the treatment period in the AQLQ(S) overall
score and domain scores. Variables evaluated for tolerability
and safety included the number of patients with AEs, vital
signs, physical examination, and the laboratory work-up.
The primary hypothesis of this study was the non-inferi-
ority of ciclesonide 80 mg once daily to fluticasone propionate
100 mg twice daily with regard to the primary variable. Non-
inferiority was also tested for the secondary variables FVC,
morning PEF from diary, and AQLQ(S) scores. The non-inferi-
ority acceptance limits were set to0.20 L for FEV1 and FVC,
25 L/min for morning PEF from diary, and0.5 for the AQLQ
(S) scores. The PP analysis was the primary analysis for
confirmatory non-inferiority testing. The ITT analysis was
performed to verify the robustness of the results.
A sample size of 382 patients (i.e., 191 patients in each
treatment group) in the PP analysis was sufficient to ensure
a power of 90% for correctly concluding non-inferiority with
regard to the primary variable under the following
assumptions: one-sided level of significance 2.5%, a mean
difference in FEV1 for ciclesonide versus fluticasone propi-
onate of 0.05 L with a standard deviation of 0.45 L, and
a non-inferiority acceptance limit of 0.20 L. Assuming
that approximately 20% of patients would not be included
in the PP analysis, a total of at least 480 patients were
required for randomization.
Primary and secondary lung function variables and AQLQ
(S) scores were evaluated by analysis of covariance,
including baseline value and age as covariates and treat-
ment, sex, and centre pool as factors. Non-inferiority was
concluded if the entire 95% confidence interval (CI) of the
difference between ciclesonide and fluticasone propionate
(least squares [LS] means) was above the predefined non-
inferiority acceptance limit.
Asthma symptom score sum and percentage of days with
asthma control were analyzed non-parametrically (level of
significance: 5%). The Wilcoxon signed-rank test modified
1124 R. Dahl et al.according to Pratt was used for within-treatment compari-
sons, and the Mann Whitney U-test was used for between-
treatment comparisons. Adverse events and other tolerability
and safety variables were analyzed descriptively.Results
Study population
Of the 625 patients who entered the run-in period, 480 were
randomized to one of the two treatment groups (ITT: cicle-
sonide 80 mg once daily, n Z 240; fluticasone propionate
100 mg twice daily, n Z 240). In total, 433 patients
completed the study, 217 patients in the ciclesonide group
and 216 patients in the fluticasone propionate groups
(Fig. 1). In the ciclesonide group, the main reason for
premature study discontinuation was patient’s request or
unwillingness to continue. In the fluticasone propionate
group, patients were withdrawn mainly because of adverse
events or other reasons (e.g., violation of randomization
criteria). All randomized patients received at least one dose
of study medication and were included in the ITT and safety
analyses. Of the 480 randomized patients, 57 were excluded
from the PP analysis because of major protocol violations
(PP, n Z 423: ciclesonide 80 mg once daily, n Z 216; fluti-
casone propionate 100 mg twice daily, n Z 207).
Slightly more never-smokers were included in the cicle-
sonide group than in the fluticasone propionate group;
otherwise, the demographic and baseline characteristics
were similar in the two treatment groups (Table 1). The
majority of patients were white, and more female than male
patients were enrolled. Most patients had mild or moderateellornE
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Figure 1 Patient flow chart. *Four patients (two in each group) w
after 24 weeks of treatment.persistent asthma (ITT: ciclesonide, 92%; fluticasone propi-
onate, 89%) according to the Global Initiative for Asthma
(GINA) 2003 classification. All except one patient in the flu-
ticasone propionate group used salbutamol during the
treatment period. Based on the diary entries, the median
compliance to study medication was 99% (range 99e100%) in
both treatment groups.
Lung function
Both treatments, ciclesonide 80 mg once daily and flutica-
sone propionate 100 mg twice daily, improved FEV1 [L] to
a similar extent during the 24-week treatment period
(Fig. 2). Improvements were statistically significant
compared to baseline at all post-baseline visits (p < 0.0001,
both groups, all time points, PP and ITT analyses). After
a rapid improvement of FEV1 during the first 2 weeks of
treatment, a plateau was reached after approximately 8
weeks of treatment; improvements remained nearly
constant until the end of the treatment period at week 24
(Fig. 2). After 24 weeks of treatment, the LS mean change
from baseline in FEV1 was 0.46 L in the ciclesonide group
and 0.52 L in the fluticasone propionate group (PP analysis);
similar results were obtained in the ITT analysis (Table 2).
Non-inferiority of ciclesonide 80 mg once daily to flutica-
sone propionate 100 mg twice daily was demonstrated for
change in FEV1 from baseline to the end of the treatment
period, since the lower limit of the 95% CI for the between-
group difference was above the predefined non-inferiority
acceptance limit of 0.20 L (PP and ITT analyses; Table 2).
The secondary lung function variables FVC and morning
PEF from diary improved statistically significantly from
baseline in the ciclesonide group and in the fluticasoned
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Table 1 Demographic data and baseline characteristics.
ITT (n Z 480) PP (n Z 423)
CIC80
(n Z 240)
FP200
(n Z 240)
CIC80 (n Z 216) FP200 (n Z 207)
Age [years], median (range) 42 (12e75) 41 (12e75) 41 (12e75) 40 (12e75)
Weight [kg], mean  SD 75  17.3 74  17.0 75  17.6 74  17.2
Height [cm], mean  SD 168  9.2 167  10.0 167  9.3 167  10.1
Sex, n (%)
Male 100 (42) 90 (38) 90 (42) 75 (36)
Female 140 (58) 150 (63) 126 (58) 132 (64)
Smoking status, n (%)
Never-smoker 187 (78) 166 (69) 166 (77) 144 (70)
Ex-/current smokera 53 (22) 74 (31) 50 (23) 63 (30)
Asthma duration [months], median (range) 121 (7e577) 124 (7e700) 117 (7e577) 121 (7e700)
ICS pretreatment [mg/day],b mean  SD 436  101 443  103 438  101 440  102
FEV1 [L], mean  SD 2.39  0.6 2.37  0.6 2.37  0.6 2.37  0.6
FEV1 [% predicted], mean  SD 75.5  6.9 76.0  6.7 75.6  6.9 75.8  6.3
Reversibility, FEV1 [% increase] 16.7  7.3 16.8  7.1 16.8  7.4 16.9  7.1
Rescue medication use [puffs/day],c median 0.86 1.00 0.86 1.00
Asthma symptom score,c,d median 0.50 0.57 0.43 0.57
CIC80 Z ciclesonide 80 mg (ex-actuator) once daily; FEV1 Z forced expiratory volume in 1s; FP200 Z fluticasone propionate 100 mg
(ex-valve, equivalent to 88 mg ex-actuator) twice daily; ICS Z inhaled corticosteroid; ITT Z intention-to-treat; PP Z per-protocol;
SD Z standard deviation.
a Ex-smoker: smoking cessation at least one year ago.
b ICS treatment up to the start of the run-in period expressed as beclomethasone dipropionate equivalent.
c Diary recordings during the week before randomization.
d Sum of daytime score (0e4) and nighttime score (0e4).
24-week efficacy of low-dose ciclesonide and fluticasone 1125propionate group (p < 0.0001, both variables, both groups,
all post-baseline visits, PP and ITT analyses; Table 2). Non-
inferiority of ciclesonide 80 mg once daily to fluticasone
propionate 100 mg twice daily was confirmed for the
changes in FVC and morning PEF from baseline to the end
of the treatment period in both the PP and ITT analyses
(Table 2).420 8 4261
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Figure 2 Time course of FEV 1 during 24 weeks of treatment
with ciclesonide or fluticasone propionate. Data are presented as
mean  standard error of the mean (PP analysis). The patient
numbers for week 0, 2, 4, 8, 16, and 24 were nZ 216, 209, 198,
195, 193, and 192 (ciclesonide), and nZ 207, 202, 197, 194, 188,
and 191 (fluticasone propionate). CIC80Z ciclesonide 80 mg (ex-
actuator) once daily; FEV1 Z forced expiratory volume in 1s;
FP200Z fluticasone propionate 100 mg (ex-valve) twice daily.Asthma control and asthma exacerbations
The median percentage of days with asthma control (i.e.,
days with no asthma symptoms and no rescue medication
use) increased significantly from baseline with both treat-
ments (p > 0.0001, both groups, PP and ITT analyses). The
baseline value was slightly higher in the ciclesonide group,
but both treatments achieved a median of 79% days with
asthma control at the end of the treatment period
(PP analysis; Fig. 3). The results were similar in the ITT
analysis: the median percentage of days with asthma control
increased from baseline to treatment end from 30% to 75% in
the ciclesonide group and from 23% to 79% in the fluticasone
propionate group. There were no statistically significant
differences between the treatment groups with regard to
the percentage of days with asthma control in both the PP
analysis (HodgeseLehmann [HL] point estimate for the
median between-treatment difference: 3.57; p Z 0.2345)
and the ITT analysis (HL point estimate: 4.25; pZ 0.1475).
Asthma exacerbations which required treatment with
oral corticosteroids occurred in 2.1% of patients (n Z 5) in
each treatment group (ITT analysis).
Quality of life
Asthma-specific quality of life improved significantly from
baseline in both treatment groups with regard to the AQLQ
(S) overall score and all domain scores (Table 3). There were
no statistically significant between-treatment differences in
the overall score or in any of the domain scores (p  0.3830,
two-sided, PP and ITT analyses). For the overall score, the LS
Table 2 Lung function measures after 24 weeks of treatment with ciclesonide or fluticasone propionate.
ITT PP
CIC80 FP200 CIC80 FP200
Change from baselinea
FEV1 [L], spirometry
n 240 239 195 193
Baseline, LS mean 2.38 2.38 2.36 2.36
Change, LS mean  SE 0.46  0.03 0.50  0.03 0.46  0.03 0.52  0.03
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
FVC [L], spirometry
n 240 239 195 193
Baseline, LS mean 3.24 3.24 3.21 3.21
Change, LS mean  SE 0.54  0.03 0.56  0.03 0.56  0.04 0.59  0.04
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Morning PEF [L/min], diary
n 234 231 189 193
Baseline, LS mean 362.9 362.9 363.5 363.5
Change, LS mean  SE 23.0  3.4 34.5  3.5 22.9  3.8 32.9  3.8
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Difference vs. fluticasone propionate
FEV1 [L], spirometry
n 240 239 195 193
Difference, LS mean  SE 0.05  0.04 0.06  0.04
95% CI 0.118, 0.024 0.138, 0.019
p-value (non-inferiority, 1-sided) <0.0001 0.0002
FVC [L], spirometry
n 240 239 195 193
Difference, LS mean  SE 0.01  0.05 0.03  0.05
95% CI 0.105, 0.076 0.126, 0.068
p-value (non-inferiority, 1-sided) <0.0001 0.0003
Morning PEF [L/min], diary
n 234 231 189 193
Difference, LS mean  SE 11.5  4.7 10.0  5.1
95% CI 20.7, 2.4 20.1, 0.1
p-value (non-inferiority, 1-sided) 0.0020 0.0018
CI Z confidence interval; CIC80 Z ciclesonide 80 mg (ex-actuator) once daily; FEV1 Z forced expiratory volume in 1s;
FP200Z fluticasone propionate 100 mg (ex-valve) twice daily; FVCZ forced vital capacity; ITTZ intention-to-treat; LSZ least squares;
PEF Z peak expiratory flow; PP Z per-protocol; SE Z standard error.
a Change from baseline to week 24 (or last [valid] recorded measurement).
1126 R. Dahl et al.mean (SE) difference between ciclesonide and fluticasone
propionate was 0.02  0.08 (95% CI: 0.17, 0.13;
p Z 0.8103) in the PP analysis and 0.05  0.07 (95% CI:
0.19, 0.09; pZ 0.5049) in the ITT analysis. Non-inferiority
of ciclesonide 80 mg once daily to fluticasone propionate
100 mg twice daily was shown for the change from baseline to
the end of the treatment period in the AQLQ(S) overall score
and all individual domain scores (p < 0.0001, one-sided, all
scores, PP and ITT analyses).
The net benefit with regard to the AQLQ(S) overall score
was comparable between the treatment groups (Table 3).
Tolerability and safety
The incidence of treatment-emergent AEs was similar in the
two groups: 44% (nZ 106) of patients treatedwith ciclesonide
80 mg once daily and 43% (nZ 103) of patients treated with
fluticasonepropionate 100 mg twice daily experienced at leastone AE. Nasopharyngitis and upper respiratory tract infection
were themost frequent AEs in both groups (Table 4). Most AEs
were mild or moderate in intensity and were assessed by the
investigator as not related or unlikely related to administra-
tion of ciclesonide or fluticasone propionate. No deaths
occurred during the study period. Two patients in each group
reported a total of four serious AEs, none of which was
assessed as being related to treatment.
There were no clinically meaningful changes in physical
examination findings and laboratory variables at the end of
the treatment period in either treatment group. Mean
blood pressure and mean heart rate were stable throughout
the study in both groups.
Discussion
The current study compared the efficacy of low-dose cicle-
sonide (80 mg/day, administered once daily in the evening)
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Figure 3 Percentage of days with asthma control, defined as
days with no asthma symptoms and no use of rescue medication,
in the ciclesonide group (nZ 203) and in the fluticasone propi-
onate group (nZ 201). Data are presented as median (PP anal-
ysis). Baseline Z interval of the last 14 days before
randomization. End of treatment periodZ interval of the last 28
days before the last recordedmeasurement. CIC80Z ciclesonide
80 mg (ex-actuator) once daily; FP200 Z fluticasone propionate
100 mg (ex-valve) twice daily.
24-week efficacy of low-dose ciclesonide and fluticasone 1127with fluticasone propionate (200 mg/day, 100 mg adminis-
tered twice daily) in patients with mild to moderate asthma.
The results showed that both treatments maintained lung
function and asthma control over a prolonged treatment
period of 24 weeks. These findings are in line with the results
of a previous double-blind study in patients with persistent
asthma, which showed similar efficacy of ciclesonide 80 mg
once daily and fluticasone propionate 100 mg twice daily
during a shorter treatment period of 12 weeks.10 As clinical
efficacy of both ciclesonide 80 mg once daily and fluticasone
propionate 100 mg twice daily has been demonstrated in
placebo-controlled studies,6,7,16 the inclusion of a placebo
arm was considered unnecessary in this study. The dose of
the active comparator fluticasone propionate of 100 mg twice
daily was chosen because it is the typical starting dose for
adult patients with mild asthma and is approved in all
countries involved in the study. Besides, information on the
efficacy of a lower daily dose of fluticasone propionate is
scarce.
On the basis of equal doses, similar efficacy of the two
corticosteroids has been shown in several 12-week studies
in patients with asthma of different severities. For
example, a randomized, double-blind study in patients 12
years with predominantly mild to moderate persistent
asthma showed that ciclesonide 160 mg once daily and flu-
ticasone propionate 100 mg twice daily were comparable in
improving lung function and in reducing asthma symptoms
and rescue medication use.17 Similar improvements in lung
function measures were also demonstrated at higher doses
in a randomized, open-label study comparing ciclesonide
320 mg once daily with fluticasone propionate 200 mg twice
daily in patients with moderate persistent asthma.18
Although the two corticosteroids showed similar efficacy in
terms of lung function and asthma control variables, there is
recent evidence that ciclesonide has beneficial effects on
small airway inflammation19 and may be more effective than
fluticasone propionate in improving peripheral lung functionin mild persistent asthma.20 The role of small airway inflam-
mation and remodelling in the pathophysiology of asthma is
not yet fully understood; however, several studies indicate
towards the necessity of targeting the central as well as the
peripheral part of the lung in asthma therapy.21e23 HFA-
based, fine particle formulations such as ciclesonide are at
a large part deposited in the periphery of the lung;24,25 they
seem to be better in controlling eosinophilic inflammation in
the small airways than more conventional formulations with
larger particle sizes.20,26,27 Optimal delivery to all regions of
the lung may be of particular importance when using reduced
corticosteroid doses.
Management of persistent asthma with inhaled cortico-
steroids depends on long-term treatment and regular intake
of the medication; discontinuation of treatment may result
in a loss of asthma control within weeks or months.28,29 To
avoid the occurrence of unwanted side effects associated
with prolonged corticosteroid treatment, modern guidelines
recommend titrating of inhaled corticosteroids to the lowest
effective dose once asthma control has been achieved.2,30,31
For the benefit of the patients, it is essential to sufficiently
explore and document the efficacy of low-dose inhaled
corticosteroids, especially in long-term treatment. A recent
study in mild asthma showed beneficial effects of prolonged
regular treatment with a minimal dose of fluticasone propi-
onate 100 mg/day to maintain the improvements achieved
with a previous higher dose of 250 mg/day32 Ciclesonide
achieves good asthma control in the majority of asthma
patients at a dose of 160 mg once daily.7,10,17,33e35 A lower
dose of ciclesonide, i.e., 80 mg once daily, is approved for
maintenance therapy in the European Union. However,
efficacy data of low-dose ciclesonide were obtained from
studies with treatment periods not exceeding 12weeks.6,7,36
The current study confirmed that low-dose ciclesonide is an
effective anti-inflammatory controller medication and
demonstrated its efficacy in mild to moderate asthma over
a prolonged treatment period of 24 weeks.
Current national and international asthma management
guidelines recommend low-dose inhaled corticosteroids as
initial controller therapy in persistent asthma. In a step-
wise treatment approach, long-acting beta-agonists can
be added to the inhaled corticosteroid in case adequate
asthma control cannot be achieved with the inhaled
corticosteroid alone.2,3 In everyday clinical practice,
combination products are increasingly used as first-line
maintenance therapy, even in mild persistent asthma.37,38
However, adding a long-acting beta-agonist to inhaled
corticosteroid appears to provide no additional benefit in
these patients and may generate unnecessary costs.39,40
Monotherapy with an inhaled corticosteroid usually ach-
ieves adequate control in a significant proportion of
patients with persistent asthma.2 In this 24-week study,
both inhaled corticosteroid monotherapy treatments
achieved good asthma control in patients with mild to
moderate persistent asthma. Asthma severity was classi-
fied according to GINA criteria. To verify the need for
inhaled corticosteroid treatment, patients had to show
a deterioration in lung function during the baseline period
after their inhaled corticosteroid had been withdrawn. As
the patients showed very good response to the low cicle-
sonide dose, it may be possible that at least some of the
patients classified as moderate actually had mild asthma.
Table 3 Improvements in asthma-specific quality of life scores and net benefit after 24 weeks of treatment with ciclesonide or
fluticasone propionate.
ITT PP
CIC80 FP200 CIC80 FP200
Change from baselinea in AQLQ(S) scores
Overall
n 226 231 191 194
Baseline, LS mean 5.51 5.51 5.53 5.53
Change, LS mean  SE 0.40  0.05 0.45  0.05 0.40  0.06 0.42  0.06
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Symptoms
n 226 231 191 194
Baseline, LS mean 5.39 5.39 5.41 5.41
Change, LS mean  SE 0.50  0.06 0.57  0.06 0.52  0.06 0.54  0.06
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Activity
n 226 231 191 194
Baseline, LS mean 5.69 5.69 5.71 5.71
Change, LS mean  SE 0.31  0.05 0.34  0.05 0.31  0.05 0.32  0.05
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Environment
n 226 231 191 194
Baseline, LS mean 5.27 5.27 5.29 5.29
Change, LS mean  SE 0.36  0.06 0.34  0.06 0.32  0.07 0.31  0.07
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Emotions
n 226 231 191 194
Baseline, LS mean 5.63 5.63 5.66 5.66
Change, LS mean  SE 0.41  0.06 0.48  0.06 0.42  0.07 0.43  0.07
p-value (2-sided) <0.0001 <0.0001 <0.0001 <0.0001
Net benefitb based on AQLQ(S) overall score
Net benefit [%] 29 31 30 29
AQLQ(S) Z Asthma Quality of Life Questionnaire (standardized version); CIC80 Z ciclesonide 80 mg (ex-actuator) once daily;
FP200 Z fluticasone propionate 100 mg (ex-valve) twice daily; ITT Z intention-to-treat; LS Z least squares; PP Z per-protocol;
SE Z standard error.
a Change from baseline to week 24 (or last [valid] recorded measurement).
b Proportion of patients with an increase of at least 0.5 in the overall score minus the proportion of patients with a decrease of at least
0.5 in the overall score.
Table 4 Treatment-emergent adverse events reported by
>3% of patients in either treatment group.
Adverse event Number (%)a of patients (ITT)
CIC80
(n Z 240)
FP200
(n Z 240)
Nasopharyngitis 26 (10.8) 25 (10.4)
Upper respiratory tract
infection
16 (6.7) 12 (5.0)
Influenza 7 (2.9) 8 (3.3)
Sinusitis 6 (2.5) 11 (4.6)
Oral candidiasis 5 (2.1) 12 (5.0)
Asthmab 5 (2.1) 9 (3.8)
CIC80 Z ciclesonide 80 mg (ex-actuator) once daily;
FP200 Z fluticasone propionate 100 mg (ex-valve) twice daily;
ITT Z intention-to-treat.
a Percentages are based on the total number of patients in
each group.
b Asthma exacerbation, asthma worsening, deterioration of
asthma, or increased symptoms of asthma.
1128 R. Dahl et al.In the general population, patients with mild persistent
asthma represent the largest proportion of all asthma
patients (up to 70%).41
Both ciclesonide 80 mg once daily and fluticasone propi-
onate 100 mg twice daily improved asthma-specific quality of
life as assessed by the standardized AQLQ. Non-inferiority of
ciclesonide to fluticasone propionate with regard to
improvements in the AQLQ(S) overall score after 24 weeks of
treatment was demonstrated. The baseline AQLQ(S) scores
were relatively high in both groups. Nevertheless, both
treatments achieved statistically significant improvements
in the AQLQ(S) overall score and all domain scores. Based on
the net benefit evaluation, approximately every third
patient had a clinically relevant improvement in quality of
life. A recent combined analysis of two 12 week, double-
blind, placebo-controlled studies in adult and adolescent
patients with mild to moderate persistent asthma showed
that all investigated ciclesonide doses (80e320 mg once
daily) significantly improved the AQLQ(S) overall scores
versus placebo (p < 0.0001).42
24-week efficacy of low-dose ciclesonide and fluticasone 1129The incidence of adverse events during the 24-week study
period was low and similar in the ciclesonide and the fluti-
casone propionate groups. Slightly more treatment-related
adverse events, which were mainly local reactions such as
oral candidiasis, were observed with fluticasone propionate
than with ciclesonide. This is not surprising, as the daily dose
of fluticasone propionate was twice as high as the daily dose
of ciclesonide. However, the incidence of local oropharyn-
geal adverse events documented in previous studies inves-
tigating comparable doses of the two inhaled corticosteroids
also indicated better local tolerability of ciclesonide.18,43
Inhaled corticosteroids generally have minimal side effects
at low to moderate doses. Nevertheless, non-compliance is
a problem in long-term asthma therapy and patients who
experience side effects are more likely to switch or dis-
continue their treatment than patients who do not.44
In summary, this 24-week study confirmed similar effi-
cacy of ciclesonide 80 mg once daily and fluticasone propi-
onate 100 mg twice daily in patients with mild to moderate
asthma and showed that low-dose ciclesonide was effica-
cious during long-term treatment. Based on these results, it
can be concluded that ciclesonide at a dose as low as 80 mg
once daily provides efficacious maintenance therapy in mild
to moderate asthma.Acknowledgments
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